Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Development and Validation of Hplc Method for Quantification of Favipiravir in Tablet


Affiliations
1 Department of Pharmaceutical Quality Assurance, D. S. T. S. Mandal’s College of Pharmacy, Solapur - 413004, Maharashtra,, India
     

   Subscribe/Renew Journal


Hplc method has been developed and validated for the quantification of Favipiravir in tablet formulation The chromatographic separation was achieved by using Luna® Phenomenex C8(150x4.6 mm,5μm) with the mobile phase comprising of water and methanol in the ratio of 95:5v/v. The flow rate was 1ml/min and the separated Favipiravir was detected at 229 nm. The retention time of Favipiravir was 4.3 minutes. The linearity data showed good linear relationship (r2= 0.9997) within the concentration range of 10-50 μg/ml. The method was successfully validated in accordance to the ICH guidelines and method was found to be sensitive, accurate, precise, and reproducible.

Keywords

Favipiravir, RP-HPLC, Validation, Method development, Method validation.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Saber-Ayad M, et al. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals (Basel). 2020 May 14;13(5):96. doi.org/10.3390/ph13050096.

  • Sohrabi C, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020 Apr;76:71-76.doi.org/10.1016/j.ijsu.2020.02.034.

  • Zhu R, et al. Systematic Review of the Registered Clinical Trials of Coronavirus Disease 2019 (COVID-19). medRxiv; 2020.doi.org/10.1101/2020.03.01.20029611.

  • Bulduk İ, et al. HPLC-UV method for quantification of favipiravir in pharmaceutical formulations. Acta Chromatographica. Jul 7, 2021;33(3):209-215.doi.org /10.1556/1326.2020.00828.

  • Dong L, et al. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 2020;14(1):58–60. doi.org/10.5582/ddt.2020.01012.

  • Chen C, et al. Favipiravir versus arbidol for COVID-19. A randomized clinical trial, medRxiv 2020;3:17–20.doi.org/10.1101/2020.03.17.20037432.

  • Murugan S, Chandra Sekhar R. Method Development and Validation of Fingolimod in Bulk and Tablet Dosage Form by RP-HPLC. Research J. Pharm. and Tech. 2017; 10(8): 2573-2576. doi.org/10.5958/0974-360X.2017.00456.5.


Abstract Views: 156

PDF Views: 0




  • Development and Validation of Hplc Method for Quantification of Favipiravir in Tablet

Abstract Views: 156  |  PDF Views: 0

Authors

M. S. Kalshetti
Department of Pharmaceutical Quality Assurance, D. S. T. S. Mandal’s College of Pharmacy, Solapur - 413004, Maharashtra,, India
Sagar G. Adlinge
Department of Pharmaceutical Quality Assurance, D. S. T. S. Mandal’s College of Pharmacy, Solapur - 413004, Maharashtra,, India

Abstract


Hplc method has been developed and validated for the quantification of Favipiravir in tablet formulation The chromatographic separation was achieved by using Luna® Phenomenex C8(150x4.6 mm,5μm) with the mobile phase comprising of water and methanol in the ratio of 95:5v/v. The flow rate was 1ml/min and the separated Favipiravir was detected at 229 nm. The retention time of Favipiravir was 4.3 minutes. The linearity data showed good linear relationship (r2= 0.9997) within the concentration range of 10-50 μg/ml. The method was successfully validated in accordance to the ICH guidelines and method was found to be sensitive, accurate, precise, and reproducible.

Keywords


Favipiravir, RP-HPLC, Validation, Method development, Method validation.

References